Parexel's New Playbook: A Plan to Remake Hematology Drug Development

RALEIGH, NC – June 10, 2026 – As thousands of the world’s leading blood disorder experts gather in Stockholm for the European Hematology Association (EHA) 2026 Congress, one company is making a particularly ambitious play. Parexel, a global clinical research organization (CRO), arrived not just with new data, but with a new doctrine. Through seven research posters and the debut of a strategic playbook, the company is signaling a shift from a service provider to a systems architect, aiming to redesign how hematology drugs move from lab to patient.

This move goes far beyond a typical conference presentation. It’s a calculated response to a field experiencing the paradoxical pressures of its own success. With breakthrough therapies transforming prognoses, the entire ecosystem of drug development is being forced to adapt. Parexel’s new resource, At the Turning Point: Shaping the Future of Hematology, is less a corporate brochure and more a candid assessment of the sector's growing pains, offering a roadmap for navigating them.

A Playbook for a New Era

The core of Parexel's announcement is its new playbook, a document born from the firm’s experience across 250 hematology programs in nearly 70 countries. It confronts a central challenge: as treatments improve, the landscape for developing the next generation of drugs becomes more complex. The playbook highlights that five-year relative survival rates for blood cancers have surged, climbing from 48% to 68% for leukemia and a staggering 32% to 62% for myeloma. While this is a monumental victory for patients, it intensifies competition for a smaller, more fragmented pool of eligible clinical trial participants.

To address this, the playbook offers tangible solutions grounded in data. One key finding reveals that deploying patient navigators in a hematology study drove a 29% decrease in the screen fail rate, a metric that can cripple trial timelines and budgets. This isn't just about patient-centricity as a buzzword; it’s about operationalizing empathy to achieve better bottom-line results.

The document also delivers a dose of hard-won realism, particularly concerning the commercialization of cutting-edge science. It notes that gene therapies for sickle cell disease and hemophilia, approved with great fanfare between 2023 and 2025, have significantly underperformed commercially. The culprit, according to Parexel's analysis, was poorly defined patient profiles during protocol design. It's a stark reminder that a scientific breakthrough is not a business plan. For drug developers, this insight is a critical, and potentially costly, lesson in the importance of integrating commercial strategy from the earliest stages of development.

Furthermore, the playbook offers a strategic shortcut for global developers, identifying China’s investigator-initiated trial (IIT) pathway as a route that can be approximately two years faster and substantially less costly than traditional IND pathways for first-in-human studies. This kind of actionable intelligence is what elevates the document from a summary of experience to a genuine strategic asset.

From Theory to Practice: The Supporting Evidence

If the playbook is the strategy guide, Parexel’s seven research posters at EHA are the real-world evidence backing it up. The presentations provide a granular look at the very challenges the playbook aims to solve, spanning some of the most dynamic areas of hematology.

Several posters tackle the rapidly evolving field of cellular and immune therapies. One study offers a real-world comparison of CAR T-cell therapies versus bispecific antibodies for Diffuse Large B-Cell Lymphoma, providing crucial data for clinicians making treatment decisions outside the pristine environment of a clinical trial. Another delves into the persistent cognitive risks—but not psychiatric ones—following CAR-T therapy, a nuanced finding that underscores the importance of long-term patient monitoring and quality of life.

“Emerging therapies in hematology are advancing at an extraordinary pace, creating new opportunities to improve patient outcomes,” said Heidi Cho, M.D., Vice President and Global Therapeutic Area Head for Hematology at Parexel. “Our research presentations and new hematology playbook reflect the depth of experience Parexel has gained... Our experiences provide actionable insights to help sponsors navigate complexity, make critical development decisions with greater confidence and help bring transformative therapies to patients faster.”

Other research speaks directly to the need for better care pathways. A study on sickle cell disease patients transitioning from pediatric to adult care examines the impact on acute care utilization, highlighting a critical vulnerability in the healthcare system that affects long-term outcomes. Another poster analyzes the regulatory divergence between the FDA and EMA in their approaches to trial design for acute myeloid leukemia, providing a much-needed map for navigating the complex and sometimes contradictory demands of global drug approval.

The Strategic Gambit

Viewed together, the playbook and the research presentations represent a sophisticated strategic maneuver in the hyper-competitive CRO market. In an industry where giants like IQVIA and Labcorp Drug Development compete for massive pharmaceutical contracts, differentiation is key. Parexel is betting that deep, actionable therapeutic expertise is the ultimate differentiator.

By publishing its playbook, the company is effectively open-sourcing its strategic thinking. It’s a move designed to position Parexel not just as a contractor that executes trial protocols, but as a strategic partner that helps design the entire development program. This shift is crucial as biopharmaceutical companies, especially smaller biotechs with lean teams, increasingly rely on their CRO partners for scientific and regulatory guidance, not just operational support.

This comprehensive showing at EHA 2026 solidifies Parexel’s claim as a thought leader in one of oncology’s most complex and fastest-moving fields. It demonstrates an understanding that the future of drug development isn't just about discovering new molecules, but about building smarter, more efficient, and more patient-focused systems to bring them to the world. By providing this level of strategic intelligence, Parexel is betting that helping its clients succeed is the surest way to secure its own future in a rapidly evolving field.